FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2072841569> ?p ?o ?g. }

• W2072841569 endingPage "628" @default.
• W2072841569 startingPage "621" @default.
• W2072841569 abstract "Opsoclonus-myoclonus is a rare syndrome characterized by multidirectional chaotic eye movements, myoclonus and ataxia. In children, it could be a paraneoplastic syndrome in association with neuroblastoma, usually with a high survival rate, but having a high frequency of neurologic and psychologic sequelae.The aim of this study was to describe oncologic outcome (prospectively) and neurologic outcome (retrospectively) in children with non-metastatic neuroblastoma, and to determine its best treatment.Data were collected on 21 children diagnosed with localized neuroblastoma and opsoclonus-myoclonus between 1990-1999 from the French Society of Pediatric Oncology institutions.Median age at diagnosis was 18 months. Location of the tumor was abdominal in 14 cases, thoracic in three cases, pelvic in three cases, and cervical in the last case. There was a majority of small tumors with a maximal diameter < 5 cm in 13 cases. Only four tumors were initially considered as unresectable tumors and received first-line chemotherapy. Complete macroscopic resection was performed in 20 cases (four after primary chemotherapy). Nine children received chemotherapy. Twenty children remained in first complete remission, and one relapsed and died (the unique NMYC amplified case). Treatment for opsoclonus-myoclonus varied widely. Only one child received no medical treatment for opsoclonus-myoclonus, because of complete resolution of neurologic symptoms after exclusive surgery. The following agents were used: corticosteroids in 18 cases, intravenously immune globulin in five cases, and antiepileptic drugs in seven cases. Ten patients experienced relapses of opsoclonus-myoclonus symptoms, mainly related to the decrease of steroid therapy (5/10). Ten of 16 assessable children had persistent neurologic deficits including speech delay or cognitive deficits (8/16), ataxia (6/16), motor delay (2/16), and behavioral problems (2/16). There is no correlation between neurologic outcome, and either age at diagnosis or duration of neurologic symptoms, or type of treatment of the tumor, particularly chemotherapy.Persistent neurologic deficits are characteristic for children with neuroblastoma and opsoclonus-myoclonus. Neurologic outcome seems unrelated to the treatment of neuroblastoma, which should exclusively be conducted according to oncological criteria. The treatment of opsoclonus-myoclonus should be standardized, mainly based on high-dose hydrocortisone, with a very low decreasing dosage, associated to intravenously immune globulin in severe cases. A biological immunologic work-up of the disease and cautious neurologic and psychologic standardized follow-up should be performed." @default.
• W2072841569 created "2016-06-24" @default.
• W2072841569 creator A5007701213 @default.
• W2072841569 creator A5017308862 @default.
• W2072841569 creator A5027448217 @default.
• W2072841569 creator A5034965143 @default.
• W2072841569 creator A5036592214 @default.
• W2072841569 creator A5049198404 @default.
• W2072841569 creator A5054447772 @default.
• W2072841569 creator A5056684913 @default.
• W2072841569 creator A5061565715 @default.
• W2072841569 creator A5067815591 @default.
• W2072841569 creator A5074101057 @default.
• W2072841569 creator A5075229558 @default.
• W2072841569 creator A5079746002 @default.
• W2072841569 date "2000-06-01" @default.
• W2072841569 modified "2023-10-01" @default.
• W2072841569 title "Syndrome opsoclonus-myoclonus associé au neuroblastome non métastatique. Suivi à long terme. Étude de la Société française d'oncologie pédiatrique" @default.
• W2072841569 cites W1854022682 @default.
• W2072841569 cites W1856657326 @default.
• W2072841569 cites W1966347172 @default.
• W2072841569 cites W1969895351 @default.
• W2072841569 cites W1979369853 @default.
• W2072841569 cites W1981028064 @default.
• W2072841569 cites W1993112105 @default.
• W2072841569 cites W2001032667 @default.
• W2072841569 cites W2003489980 @default.
• W2072841569 cites W2005154888 @default.
• W2072841569 cites W2025812819 @default.
• W2072841569 cites W2030543234 @default.
• W2072841569 cites W2044341604 @default.
• W2072841569 cites W2051846016 @default.
• W2072841569 cites W2052647534 @default.
• W2072841569 cites W2054702834 @default.
• W2072841569 cites W2055299435 @default.
• W2072841569 cites W2062517012 @default.
• W2072841569 cites W2068608237 @default.
• W2072841569 cites W2074484593 @default.
• W2072841569 cites W2082899925 @default.
• W2072841569 cites W2091986391 @default.
• W2072841569 cites W2096398040 @default.
• W2072841569 cites W2121200845 @default.
• W2072841569 cites W2124590494 @default.
• W2072841569 cites W2311461176 @default.
• W2072841569 doi "https://doi.org/10.1016/s0929-693x(00)80129-3" @default.
• W2072841569 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/10911528" @default.
• W2072841569 hasPublicationYear "2000" @default.
• W2072841569 type Work @default.
• W2072841569 sameAs 2072841569 @default.
• W2072841569 citedByCount "36" @default.
• W2072841569 countsByYear W20728415692012 @default.
• W2072841569 countsByYear W20728415692013 @default.
• W2072841569 countsByYear W20728415692014 @default.
• W2072841569 countsByYear W20728415692015 @default.
• W2072841569 countsByYear W20728415692016 @default.
• W2072841569 countsByYear W20728415692017 @default.
• W2072841569 countsByYear W20728415692018 @default.
• W2072841569 countsByYear W20728415692021 @default.
• W2072841569 countsByYear W20728415692022 @default.
• W2072841569 countsByYear W20728415692023 @default.
• W2072841569 crossrefType "journal-article" @default.
• W2072841569 hasAuthorship W2072841569A5007701213 @default.
• W2072841569 hasAuthorship W2072841569A5017308862 @default.
• W2072841569 hasAuthorship W2072841569A5027448217 @default.
• W2072841569 hasAuthorship W2072841569A5034965143 @default.
• W2072841569 hasAuthorship W2072841569A5036592214 @default.
• W2072841569 hasAuthorship W2072841569A5049198404 @default.
• W2072841569 hasAuthorship W2072841569A5054447772 @default.
• W2072841569 hasAuthorship W2072841569A5056684913 @default.
• W2072841569 hasAuthorship W2072841569A5061565715 @default.
• W2072841569 hasAuthorship W2072841569A5067815591 @default.
• W2072841569 hasAuthorship W2072841569A5074101057 @default.
• W2072841569 hasAuthorship W2072841569A5075229558 @default.
• W2072841569 hasAuthorship W2072841569A5079746002 @default.
• W2072841569 hasConcept C118552586 @default.
• W2072841569 hasConcept C141071460 @default.
• W2072841569 hasConcept C187212893 @default.
• W2072841569 hasConcept C2776538686 @default.
• W2072841569 hasConcept C2776694085 @default.
• W2072841569 hasConcept C2776715637 @default.
• W2072841569 hasConcept C2780189975 @default.
• W2072841569 hasConcept C2780906641 @default.
• W2072841569 hasConcept C42219234 @default.
• W2072841569 hasConcept C54355233 @default.
• W2072841569 hasConcept C71924100 @default.
• W2072841569 hasConcept C81885089 @default.
• W2072841569 hasConcept C86803240 @default.
• W2072841569 hasConceptScore W2072841569C118552586 @default.
• W2072841569 hasConceptScore W2072841569C141071460 @default.
• W2072841569 hasConceptScore W2072841569C187212893 @default.
• W2072841569 hasConceptScore W2072841569C2776538686 @default.
• W2072841569 hasConceptScore W2072841569C2776694085 @default.
• W2072841569 hasConceptScore W2072841569C2776715637 @default.
• W2072841569 hasConceptScore W2072841569C2780189975 @default.
• W2072841569 hasConceptScore W2072841569C2780906641 @default.
• W2072841569 hasConceptScore W2072841569C42219234 @default.
• W2072841569 hasConceptScore W2072841569C54355233 @default.
• W2072841569 hasConceptScore W2072841569C71924100 @default.

• next